Work Underway To Demystify Why Regulators Respond Differently To Drug Safety Issues
An independent UK-based pharmacovigilance unit has begun exploring and analyzing why national regulatory authorities across the globe respond differently to the same post-marketing concerns.
You may also be interested in...
AZ Vaccine Safety: Germany Introduces Age Restrictions, But EMA Says Rare Blood Clot Link Still Unproven
The European Medicines Agency will reach its scientific conclusion next week, but countries are already moving to restrict use of the vaccine.
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a newly-created regulatory oversight group has identified several topics requiring further scientific discussion.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.